Silence Therapeutics surges after positive Phase 2 divesiran data

Silence Therapeutics (SLN) is up 35.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp move appears to be driven mainly by positive topline Phase 2 SANRECO results for divesiran in polycythemia vera, released before the market opened. The company also paired that clinical update with second-quarter financial results showing a lower net loss and a cash balance that supports continued development, which likely added to the bullish reaction.

Details:

The Phase 2 study met its primary endpoint, with an 88% clinical response rate for divesiran versus 19% for placebo in phlebotomy-dependent patients.

Both dosing schedules showed strong activity, with response rates of 93.8% for every-six-week dosing and 81.3% for every-twelve-week dosing, while safety was described as consistent with prior studies and no new safety findings were observed.

The company said the key secondary endpoint was also met, with mean phlebotomies per patient reduced to 0.2 in the divesiran groups versus 2.1 for placebo, alongside improvements in hematocrit control, iron markers, and symptom scores.

Management said a Phase 3 trial evaluating quarterly dosing versus placebo is expected to begin in the first half of 2027, while second-quarter results showed cash and cash equivalents of $72.1 million and net loss narrowing to $12.3 million.

Sources:

Silence Therapeutics, SEC, StockTitan

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$SLN Hedge Fund Activity

We have seen 28 institutional investors add shares of $SLN stock to their portfolio, and 16 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CITADEL ADVISORS LLC added 990,746 shares (+405.9%) to their portfolio in Q1 2026, for an estimated $5,221,231
NANTAHALA CAPITAL MANAGEMENT, LLC added 604,304 shares (+39.2%) to their portfolio in Q1 2026, for an estimated $3,184,682
MILLENNIUM MANAGEMENT LLC added 414,599 shares (+62.9%) to their portfolio in Q1 2026, for an estimated $2,184,936
SG AMERICAS SECURITIES, LLC removed 274,642 shares (-95.8%) from their portfolio in Q2 2026, for an estimated $3,015,569
TETRAGON PARTNERS GP LTD added 264,792 shares (+72.5%) to their portfolio in Q1 2026, for an estimated $1,395,453
MORGAN STANLEY removed 259,144 shares (-79.8%) from their portfolio in Q1 2026, for an estimated $1,365,688
LOMBARD ODIER ASSET MANAGEMENT (USA) CORP removed 255,901 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,348,598

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$SLN Analyst Ratings

Wall Street analysts have issued reports on $SLN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Cantor Fitzgerald issued a "Overweight" rating on 06/24/2026
HC Wainwright & Co. issued a "Buy" rating on 03/13/2026

To track analyst ratings and price targets for $SLN, check out Quiver Quantitative's $SLN forecast page.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.